Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| EVAMED | OTHER |
Not provided
Not provided
Not provided
Not provided
As the medical device is CE marked, the objective of this study is to provide performance and safety data on SULFEX 13081.22 nasal spray as close as possible to the routine care.
Every day, people breathe large amounts of air which contain all kinds of particles. Nasal cavities are the first site of airway protection against airborne particles. The mucociliary apparatus (a layer of tiny moving hairs and mucus which covers the mucous membrane inside the nose) is the first line of defence of the upper airways and helps to eliminate these particles. If this defence mechanism is altered, it may cause nasosinusal damage or irritation and be unable to protect the respiratory system.
Moreover, external factors such as pollution or dry air may affect the function of the nose. The same is true for chronic and/or recurrent infections. These various factors can cause irritation or dryness of the nasal mucosa, often causing inflammation with feelings of congestion, discomfort or burning of the nasal mucosa, sometimes with bleeding or painful crusting.
SULFEX 13081.22 is a nasal spray, CE marked and commercialized since 2014. SULFEX spray soothes, restores and provides long-lasting/intense hydration of uncomfortable, painful or sore nasal mucosa caused by excessive dryness. It also contributes towards cell regeneration for faster healing and optimum relief and protects against new external attacks.The anti-reflux valve system prevents any contamination of the solution, even after the bottle has been opened, which means the formula remains 100% aseptic.
As the medical device is CE marked, the objective of this study is to provide performance and safety data on SULFEX 13081.22 nasal spray as close as possible to the routine care.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SULFEX 13081.22 | Experimental | Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SULFEX 13081.22 | Device | Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis. |
| Measure | Description | Time Frame |
|---|---|---|
| Nasal symptoms severity | Severity of the following nasal symptoms will be compared before and 6 days after spray use on a 7-point scale basis.
| 6 days |
| Measure | Description | Time Frame |
|---|---|---|
| Safety data on SULFEX 13081.22 nasal spray | To collect safety data on the SULFEX 13081.22 nasal spray after 6 days of use (with at least 1 spray use a day). Proportion of patients with at least one adverse device effect occurred between the first and the last spray use. | 6 days |
| Performance of SULFEX 13081.22 nasal spray |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Timothé GOUDOT, Pharmacist | Contact | 0033145431554 | plaisancepharmacie@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pharmacie Lair | Recruiting | Vire | Normandy | 14500 | France |
Not provided
| ID | Term |
|---|---|
| D015508 | Nasal Obstruction |
| D004844 | Epistaxis |
| D012912 | Sneezing |
| ID | Term |
|---|---|
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D000402 | Airway Obstruction |
| D012131 | Respiratory Insufficiency |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the performance of the SULFEX 13081.22 nasal spray, on the following nasal symptoms, after 6 days of use (with at least 1 spray use a day).
This item is scaled from 0 to 3, with 0.5 increments and 3 being the worst value. |
| 6 days |
| Nasal symptoms relief/change | To assess nasal symptoms relief/reduction each day, from Day 0 to Day 6. Assessment of nasal symptoms mean scores at D0 / D1 / D2 / D3 / D4 / D5 and D6. This item is scaled from 0 to 3, with 0.5 increments and 3 being the worst value. | 6 days |
| Onset of relief | To assess onset of relief (immediate or semi-immediate relief). Proportion of patients with immediate or semi-immediate relief. An immediate relief is defined as a nasal symptom improvement at 1 min or 10 min after the 1st spray use of the day. A semi-immediate relief is defined as a nasal symptom improvement at 1 hour after the 1st spray use of the day. | immediate or semi-immediate |
| Duration of relief (long lasting). | To assess duration of relief (long lasting). This item is scaled from 0 to 3, with 0.5 increments and 3 being the worst value. | 6 days |
| Previous nasal state of well-being assessment | To assess the day at which patients regained their previous nasal state of well-being (feeling of well-being). Day at which the patient regained his/her previous nasal state of well-being (feeling of well-being) + proportion of patients with an overall relief. This item is scaled from 0 to 3, with 0.5 increments and 3 being the worst value. | 6 days |
| Medical device usability | To assess the medical device usability. assessment of the proportion of patients that would agree with each usability criteria on a 5-point scale basis. This item is scaled from 1 to 5, with 1 increments and 1 being the worst value. | 6 days |
| Product attributes | To assess product attributes of the medical device. Assessment of proportion of patients that would agree with each product attribute on a 5-point scale basis. This item is scaled from 1 to 5, with 1 increments and 1 being the worst value. | 6 days |
| Patient satisfaction | To assess patient satisfaction regarding the medical device. Assessment of Proportion of patients satisfied with the medical device use on a 5-point scale basis.
This item is scaled from 1 to 5, with 1 increments and 1 being the worst value. | 6 days |
| Pharmacie Plaisance | Recruiting | Paris | 75014 | France |
|
| D012120 |
| Respiration Disorders |
| D010038 | Otorhinolaryngologic Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |